Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CardiAQ Valve Technologies

This article was originally published in Start Up

Executive Summary

Today, mitral valve repair and replacement procedures involve opening the chest and stopping the heart. Hence, many patients who might otherwise benefit from therapy are excluded because they are either too ill or not ill enough to justify the risk. A percutaneous mitral valve replacement system in development from CardiAQ Valve Technologies intends to significantly reduce that risk by using a catheter to deliver a new mitral valve.

You may also be interested in...



Start-Up Previews (06/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Set Sights on Flu," features profiles of Alios BioPharma, Immune Targeting Systems, Marinomed Biotechnologie and Vivaldi Biosciences. Plus these Start-Ups Across Health Care: CardiAQ Valve Technologies, NKT THerapeutics, SPOC Inc.,and Sutro Biopharma.

Start-Up Previews (06/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Set Sights on Flu," features profiles of Alios BioPharma, Immune Targeting Systems, Marinomed Biotechnologie and Vivaldi Biosciences. Plus these Start-Ups Across Health Care: CardiAQ Valve Technologies, NKT THerapeutics, SPOC Inc.,and Sutro Biopharma.

Percutaneous Heart Valve Technology: The Mitral Challenge

While there is no question that heart valve repair and replacement is moving toward minimally invasive techniques and devices, there is a big difference between a minimally invasive surgical approach and a truly percutaneous, incisionless procedure. The challenges of reaching the latter goal are substantial, but apparently not insurmountable., In fact, recent progress in this field provides hope that in the not too distant future, percutaneous valve replacement and repair will become an accepted part of the treatment armamentarium, greatly expanding the number of patients who can be offered these potentially life-saving procedures.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

MT037610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel